相关实验视频

Updated: Jul 6, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

癌症残留负担指数作为新辅助化疗后乳腺癌的有效预后指标

Xin Xu^1,2, Wei Zhao³, Cuicui Liu⁴

¹Tianjin Medical University Cancer Institute & Hospital,National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300000, China.

|January 3, 2024

概括

剩余癌症负担 (RCB) 指数有效预测接受新辅助化疗 (NAC) 的中国乳腺癌患者的无复发生存期 (RFS). 高RCB得分表明复发风险增加,指导治疗决策.

科学领域:

在瘤学瘤学.
临床研究临床研究
生物标志物开发生物标志物开发

背景情况:

新辅助化疗 (NAC) 是乳腺癌的标准治疗方法.
响应评估标准对于评估治疗疗效至关重要.
癌症残留负担指数 (RCB) 是为了量化治疗反应而开发的.

研究的目的:

评估残留癌症负担 (RCB) 指数在预测乳腺癌患者无复发生存率 (RFS) 中的相关性.
评估临床病理因素与RFS之间的关联.
探索RCB作为预后生物标志物的潜力.

主要方法:

对254名接受NAC.治疗的乳腺癌患者的回顾性分析.
考克斯的比例危险回归和卡普兰-梅尔分析RFS.
多变量物流回归用于确定RCB风险因素.
对生物标志物潜力的接收器操作特征 (ROC) 曲线分析.

主要成果:

高RCB得分是复发的重要危险因素 (P=0.003).
病理完整反应 (RCB 0) 与HER2阳性和三阴性乳腺癌 (TNBC) 有关.
RCB的预后值为0.691的AUC,超过了MP得分 (AUC=0.342).

结论:

RCB指数是预测中国接受NAC.乳腺癌患者的RFS的一个有价值的工具.
瑞银可以帮助指导选择个性化治疗策略.
进一步的研究可能会验证RCB在不同患者群体中的作用.

关键词:

乳腺癌是什么? 乳腺癌是什么米勒 - 佩恩分级的分级.新辅助化学疗法新辅助化学疗法病理学完整的反应反应.剩余的癌症负担是癌症负担.

更多相关视频

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...